Day: June 7, 2021

Radiosurgery Market 2021 | Size, Share, Growth, Trends, Competitive Landscape, Analysis, Revenue, Forecast Research Report

Written by Customer Service on June 7, 2021. Posted in Mergers And Acquisitions.

Key Prominent Players Covered in the Radiosurgery Market Research Report Are IsoRay, Inc., Mallinckrodt Public Limited, Siemens, Ion Beam Applications SA, Mevion Medical Systems, Inc., Varian Medical Systems, R. Bard, Inc., Accuray Incorporated Pune, India, June 07, 2021 (GLOBE NEWSWIRE) — Rising number of patients battling brain tumor is expected to fuel the global radiosurgery market growth, according to Fortune Business Insights in its report, titled “Radiosurgery Market”, Size, Share and Global Trend By Indication (Cobalt 60 Systems (Gamma Knife), Electron-Emitting High-Energy Linear Accelerators(Linac), Proton Beam Therapy), By End User (Hospitals, Clinics, Others) and Geography Forecast till 2026”. A detailed assessment of the key factors determining the growth and development pattern of the market has also been incorporated...

Gentex Announces Second Quarter 2021 Cash Dividend

Written by Customer Service on June 7, 2021. Posted in Dividend Reports And Estimates.

ZEELAND, Mich., June 07, 2021 (GLOBE NEWSWIRE) — Gentex Corporation (NASDAQ: GNTX), the Zeeland, Michigan-based supplier of digital vision, connected car, dimmable glass, and fire protection technologies, today announced that its Board of Directors recently declared a quarterly cash dividend of $0.12 (12 cents) per share that will be payable July 21, 2021, to shareholders of record of the common stock at the close of business on July 9, 2021. About the CompanyFounded in 1974, Gentex Corporation (The NASDAQ Global Select Market: GNTX) is a supplier of automatic-dimming rearview mirrors and electronics to the automotive industry, dimmable aircraft windows for aviation markets, and fire protection products to the fire protection market. Visit the Company’s websites at www.gentex.com, fulldisplaymirror.com, and gentextech.com. Contact...

Terra Tech Corp. Strengthens Balance Sheet with Monetization of Legacy Real Estate

Written by Customer Service on June 7, 2021. Posted in Public Companies.

SANTA ANA, Calif., June 07, 2021 (GLOBE NEWSWIRE) — Terra Tech Corp. (OTCQX:TRTC) (“Terra Tech” or the “Company”) today announced that the Company entered into an agreement for the sale of its non-operating N. 4th Street property in Las Vegas, NV. Based on local zoning changes, the property cannot be used for any cannabis related activities. The sale price of $2.6M results in an approximate $900K balance sheet improvement, after paying off the existing $1.6M mortgage on the property and related sales fees. The sale also eliminates the current monthly burn of carrying the property, including mortgage, taxes, and other associated costs. The closing of the sale is subject to customary conditions and is expected to occur by early August 2021. Frank Knuettel, Chief Executive Officer of Terra Tech, stated, “Since...

Hill International to Manage On-Call Professional Service Program for Los Angeles World Airports

Written by Customer Service on June 7, 2021. Posted in Public Companies.

PHILADELPHIA and LOS ANGELES, June 07, 2021 (GLOBE NEWSWIRE) — Hill International (NYSE:HIL), delivering the infrastructure of change, announced today it was selected by Los Angeles World Airports (LAWA), a Department of the City of Los Angeles, to manage airport concessions development, tenant projects, and airport commercial analysis and development at LAWA properties including Los Angeles International Airport (LAX), Van Nuys Airport (VNY), and Palmdale Landholdings. Work will be carried out through task-order contracts under a three-year indefinite delivery/indefinite quantity contract with two potential one-year extensions. Task orders will encompass a range of projects to improve the use and efficiency of airport properties. The Hill team is organized around two areas of expertise: commercial and technical advisory services....

Veru Announces Positive Phase 1b/2 Clinical Study Update for Sabizabulin (VERU-111) in Men with Metastatic Castration Resistant Prostate Cancer Presented at the 2021 ASCO Annual Meeting

Written by Customer Service on June 7, 2021. Posted in Public Companies.

— Sabizabulin, an oral selective cytoskeleton disruptor, demonstrated good safety, significant evidence of antitumor efficacy, and that chronic administration is feasible in ongoing Phase 1b/2 study of 80 men — — Phase 3 VERACITY study to evaluate sabizabulin treatment in men who have metastatic castration prostate cancer and have also progressed following at least one androgen receptor targeting agent planned to start this month — MIAMI, June 07, 2021 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer, today announced the presentation of the Phase 1b/2 clinical trial update of sabizabulin (VERU-111), an oral cytoskeleton disruptor which in prostate cancer also disrupts androgen receptor...

Impel NeuroPharma Announces First Quarter 2021 Financial Results and Provides Business Update

Written by Customer Service on June 7, 2021. Posted in Earnings Releases And Operating Results.

– Completed successful IPO raising approximately $80.0 million in gross proceeds –– NDA for TRUDHESA for treatment of acute migraine accepted for review by FDA; PDUFA date of September 6, 2021 –– Strengthened commercial capabilities with expanded management team and strategic collaboration with Veeva Systems – SEATTLE, June 07, 2021 (GLOBE NEWSWIRE) — Impel NeuroPharma, Inc. (NASDAQ: IMPL), a late-stage pharmaceutical company focused on utilizing its proprietary POD® technology to develop and commercialize transformative therapies for patients suffering from diseases with high unmet medical needs, today reported financial results for the first quarter ended March 31, 2021 and produced a recent business update. “The past quarter and recent months were marked by significant financial and clinical milestones for Impel as we execute...

Inari Medical Announces Late-Breaking CLOUT Registry Data Demonstrating Long-Term Benefits of Lytic-Free Single-Session Near Bloodless Thrombectomy in First 250 Real-World DVT Patients

Written by Customer Service on June 7, 2021. Posted in Public Companies.

Inari Medical CLOUT registry 250 patient 6 mo dataInari Medical CLOUT registry 250 patient 6 mo dataIRVINE, Calif., June 07, 2021 (GLOBE NEWSWIRE) — Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today announced strongly positive interim results of the first 250 deep vein thrombosis (“DVT”) patients enrolled in the ClotTriever Outcomes Registry (“CLOUT”). This latest data showed that ClotTriever removed 100% of the blood clots in the majority of DVT patients without the need for thrombolytic drugs in short single-session procedures. The late-breaking data was presented virtually at NCVH 2021 by principal investigator, Robert Beasley, MD, an interventional radiologist at Palm Vascular...

Retail Clinics Market 2021 | Size, Share, Growth, Trends, Analysis, Competitive Landscape, Forecast Report

Written by Customer Service on June 7, 2021. Posted in Mergers And Acquisitions.

Key Prominent Players Covered in the retail clinics market are Bellin Health Systems, Walgreen Co., CVS Health, NextCare, Rite Aid Corp, The Kroger Co., RediClinic, Kaiser Foundation Health Plan, Inc., Shopko Stores Operating Co., LLC, Geisinger Health, Sutter Health, and others. Pune, India, June 07, 2021 (GLOBE NEWSWIRE) — Rising prevalence of communicable diseases around the world is driving the global retail clinics market, says Fortune Business Insights in a report, titled “Retail Clinics Market Size, Share and Global Trend by Location (Departmental Stores, Shopping Malls, Retail Stores, Others) By Ownership (Standalone, Hospital-owned, Investor-owned, Others), By Mode of Payment (Insurance, Out-of-Pocket) and Geography Forecast till 2026.” Improved accessibility of healthcare for the geriatric population is a key factor predicted...

Simmons First National Corporation Announces Agreements to Acquire Landmark Community Bank and Triumph Bancshares, Inc.

Written by Customer Service on June 7, 2021. Posted in Mergers And Acquisitions.

Acquisitions will complement existing footprint and enhance scale in Memphis and Nashville; will create the 9th largest bank in Tennessee based on deposit market share PINE BLUFF, Ark., June 07, 2021 (GLOBE NEWSWIRE) — Simmons First National Corporation (NASDAQ: SFNC) (“Simmons” or “Company”) announced today that it has entered into two separate definitive agreements to acquire Landmark Community Bank (“Landmark”), based in Collierville, Tenn., and Triumph Bancshares, Inc. (“Triumph”), the parent company of Triumph Bank, based in Memphis, Tenn. On a pro forma basis, the proposed Landmark and Triumph transactions (together, the “Proposed Transactions”) will create the 9th largest bank in Tennessee (based upon deposit market share) while vaulting Simmons’ ranking in Memphis from 35th to 6th and in Nashville from 20th...

Salarius Pharmaceuticals Presents New Research Data Demonstrating Seclidemstat’s Safety, Dosing, and Drug Activity at American Society of Clinical Oncology (ASCO) 2021 Annual Meeting

Written by Customer Service on June 7, 2021. Posted in Public Companies.

Presentations highlight full data from dose-escalation stage of Phase 1/2 clinical trial in Ewing sarcoma and interim data from Advanced Solid Tumor (AST) trial Initial drug activity observed in both relapsed/refractory Ewing sarcoma and AST trials Advanced FET-rearranged sarcoma patients in AST trial demonstrated stable disease and prolonged time to progression suggestive of disease control, a clinically relevant endpoint for soft tissue sarcomas HOUSTON, June 07, 2021 (GLOBE NEWSWIRE) — Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, presented key findings from clinical research involving its lead drug candidate, seclidemstat. These results, disclosed in poster presentations at the...

M	T	W	T	F	S	S
	1	2	3	4	5	6
7	8	9	10	11	12	13
14	15	16	17	18	19	20
21	22	23	24	25	26	27
28	29	30

Day: June 7, 2021

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals